MAX BioPharma is pleased to announce that it has been awarded a Phase IIB grant in continuation of the successful completion of our Phase II award to develop an effective compound for intervention in osteoporosis by stimulating bone formation in patients that have lost bone. Such bone anabolic therapies are rare and MAX BioPharma is poised to develop novel bone anabolic agents. We are excited that our groundbreaking efforts will provide patients with osteoporosis new ways to treat their devastating disease that results in bone fractures, morbidity, and mortality.